NCT05564390 2026-04-15
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Recruiting
Clinical Trials
60 trialsNCT03896269 2026-04-14
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT05554406 2026-04-14
Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT05554419 2026-04-13
Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Not yet recruiting
NCT04049539 2026-04-08
Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After Induction
Ohio State University Comprehensive Cancer Center
Phase 1/2 Recruiting
NCT04990102 2026-03-23
Phase IB/II of CPX-351 for Relapse Prevention in AML
Georgetown University
Phase 1/2 Recruiting
NCT05627232 2026-03-12
Tazemetostat and Palbociclib With CPX-351for R/R AML
Thomas Jefferson University
Phase 1 Recruiting
NCT03226418 2026-03-10
Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia
University of Nebraska
Phase 2 Completed
NCT04231851 2026-03-06
CPX-351 and Glasdegib for Newly Diagnosed Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid Leukemia
University of California, Irvine
Phase 2 Active not recruiting
NCT02286726 2026-03-04
CPX-351 in Treating Patients With Newly Diagnosed, High-Risk Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 2 Completed
NCT05558124 2026-02-27
CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Recruiting
NCT04293562 2026-02-24
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Children's Oncology Group
Phase 3 Recruiting
NCT03629171 2026-02-20
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT03672539 2026-02-20
Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04915612 2026-02-20
Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatric Patients With Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 1 Completed
NCT03826992 2026-02-18
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
Children's Hospital Medical Center, Cincinnati
Phase 1 Recruiting
NCT05656248 2026-02-04
Study of CPX-351 (VYXEOS) in Individuals < 22 Years With Secondary Myeloid Neoplasms
St. Jude Children's Research Hospital
Phase 2 Active not recruiting
NCT04802161 2025-12-19
Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04128748 2025-12-17
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT04493164 2025-11-21
CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06143839 2025-11-20
VYSION
Jazz Pharmaceuticals
Completed
NCT03878199 2025-09-15
Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms
Ohio State University Comprehensive Cancer Center
Phase 1/2 Completed
NCT03897127 2025-07-17
Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics
University of Ulm
Phase 3 Active not recruiting
NCT04668885 2025-07-15
CPX-351 as a Novel Approach for the Treatment of Older Patients With AML and MDS
Case Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT04195945 2025-07-10
CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients
Fred Hutchinson Cancer Center
Phase 2 Active not recruiting
NCT07008638 2025-07-09
Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)
Masonic Cancer Center, University of Minnesota
Phase 1/2 Recruiting
NCT03844997 2025-05-31
Phase I/II Trial of CPX-351 + Palbociclib in Patients With Acute Myeloid Leukemia
Case Comprehensive Cancer Center
Phase 1/2 Completed
NCT03575325 2024-12-12
Vyxeos(CPX-351) in Adults w R/R Acute Lymphoblastic Leukemia
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT05599360 2024-12-02
Vyxeos for Induction of Low- or Intermediate-risk.
Shaare Zedek Medical Center
Phase 2 Active not recruiting
NCT04992949 2024-10-29
CPX-351 TA-SMP
French Innovative Leukemia Organisation
Phase 2 Completed
NCT04982354 2024-10-01
Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia
Baptist Health South Florida
Phase 1/2 Withdrawn
NCT05628623 2024-07-03
ERASE
Eastern Cooperative Oncology Group
Phase 2 Not yet recruiting
NCT04526288 2024-05-23
CPX-351 Versus Immediate Stem Cell Transplantation for the Treatment of High-Grade Myeloid Cancers With Measurable Residual Disease
Fred Hutchinson Cancer Center
Phase 2 Terminated
NCT03335267 2024-02-22
Investigator Initiated Trial of CPX-351 for Untreated Acute Myeloid Leukemia
Weill Medical College of Cornell University
Phase 2 Completed
NCT05829434 2024-02-12
MAGROLIC
University of Leipzig
Phase 2 Withdrawn
NCT04209725 2023-12-05
A Study of CPX-351 (Vyxeosâ„¢) With Quizartinib for the Treatment of FLT3-ITD Mutation-Positive Acute Myeloid Leukemia
SCRI Development Innovations, LLC
Phase 2 Terminated
NCT03904251 2023-11-18
CPX-351 and Gemtuzumab Ozogamicin in Treating Patients With Relapsed Acute Myeloid Leukemia
Jonsson Comprehensive Cancer Center
Phase 1 Terminated
NCT04075747 2023-10-16
V-FAST
Jazz Pharmaceuticals
Phase 1 Completed
NCT03825796 2023-09-28
CPX-351 Plus Enasidenib for Relapsed AML
Jonsson Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT05801835 2023-09-21
A Bioequivalence Study of (Cytarabine: Daunorubicin) Liposome for Injection
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Phase NA Unknown
NCT05320380 2023-09-01
A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat
Children's Oncology Group
Phase 1/2 Withdrawn
NCT04217278 2023-05-10
COSI
University of Birmingham
Phase 2/3 Unknown
NCT03878927 2023-03-10
CPX GO
Weill Medical College of Cornell University
Phase 1 Terminated
NCT03393611 2022-12-21
CPX-351 Salvage Therapy Followed by Haplo-Cord Transplant for Relapsed/Refractory Leukemia or Myelodysplastic Syndrome
Weill Medical College of Cornell University
Phase 1 Completed
NCT04038437 2022-11-09
A Trial of CPX-351 Lower Intensity Therapy (LIT) Plus Venetoclax as First Line Treatment for Subjects With AML
Jazz Pharmaceuticals
Phase 1 Completed
NCT04425655 2022-09-22
Fludarabine in Combination With Daunorubicin and Cytarabine Liposome in Newly-diagnosed Acute Myeloid Leukemia.
University of California, San Diego
Phase 2 Terminated
NCT03988205 2022-07-19
Patients Receiving Induction With Liposomal Daunorubicin and Cytarabine (CPX-351) for Acute Myeloid Leukemia
Medical College of Wisconsin
Phase 4 Terminated
NCT05169307 2022-07-12
CPX-351 Real-World Effectiveness and Safety Study
Jazz Pharmaceuticals
Completed
NCT03555955 2021-07-22
A Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351
Jazz Pharmaceuticals
Phase 1 Completed
NCT01943682 2020-11-09
Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma
Children's Hospital Medical Center, Cincinnati
Phase 1 Completed